Almirall welcomes UCB head into Board of directors

pharmafile | October 29, 2012 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing |  Almirall, Gerhard Mayr 

Almirall has approved the appointment of Gerhard Mayr as a new independent member to its Board of directors.

He is currently president of the Board of directors of UCB and a member of the Board at Lonza. The Austrian chemical engineer has extensive international experience in the healthcare sector and has managed several business models in pharma.

Mayr’s career spans over 40 years in a variety of companies within the pharmaceutical sector. His strategic vision, outstanding innovative capacity, leadership in stock market environments and extensive international experience advocate his appointment as Board member, Almirall add.

Advertisement

Headquartered in Barcelona, Almirall researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and wellbeing with a focus on respiratory, gastrointestinal, dermatology and pain.

Related Content

Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment

Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk …

Almirall gains EC approval of Ebglyss for moderate-to-severe atopic dermatitis

Almirall has announced that the European Commission (EC) has approved Ebglyss (lebrikizumab) for the treatment …

The Gateway to Local Adoption Series

Latest content